首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter,randomized, double-blind,placebo-controlled,parallel-group trial in Japanese and Korean patients
Authors:Fumihiko Sakai MD  PhD  Norihiro Suzuki MD  PhD  Byung-Kun Kim MD  PhD  Hisaka Igarashi MD  PhD  Koichi Hirata MD  PhD  Takao Takeshima MD  PhD  Xiaoping Ning MD  MS  Tomoko Shima BS  Miki Ishida BS  Katsuhiro Iba MS  Hiroyuki Kondo BA  Nobuyuki Koga MS
Affiliation:1. Saitama International Headache Center, Saitama Neuropsychiatric Institute, Saitama, Japan;2. Department of Neurology, Shonan Keiiku Hospital, Kanagawa, Japan;3. Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea;4. Headache Care Unit, Department of Internal Medicine, Fujitsu Clinic, Kanagawa, Japan;5. Headache Center, Department of Neurology, Dokkyo Medical University, Tochigi, Japan;6. Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan;7. Specialty Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA;8. Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan;9. Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan;10. Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
Abstract:
Keywords:calcitonin gene-related peptide  chronic migraine  fremanezumab  Japanese  Korean
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号